Improved short-term spatial memory but impaired following the dopamine D-2 agonist bromocriptine reversal learning in human volunteers

M A Mehta, Rachel Swainson, A D Ogilvie, B J Sahakian, T W Robbins

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Rationale: Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function. Objectives: This study was designed to investigate the effects of 1.25 mg of the dopamine D-2 agonist bromocriptine on spatial working memory, planning and discrimination reversal learning in young healthy volunteers. Methods: Twenty volunteers were tested in a double-blind, placebo-controlled, crossover design. The cognitive assessment included tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) designed to test visuospatial recognition memory and spatial working memory. In addition, tests of spatial planning and discrimination reversal learning were used to assess the more general effects of bromocriptine. Tests of subjective feelings and motivation were also incorporated into the battery. Results: Bromocriptine enhanced the spatial memory span of subjects, whilst impairing their ability to reverse a learned probabilistic discrimination. Tests of recognition memory and planning were unaffected by the drug. The findings were not explained by chances in subjective mood or motivational measures. Conclusions: The pattern of findings observed here mirror medication-dependent observations seen in Parkinson's disease. The results, are discussed with reference to the different anatomical networks known to subserve performance of the differentially affected tasks.

Original languageEnglish
Pages (from-to)10-20
Number of pages11
JournalPsychopharmacology
Volume159
Issue number1
DOIs
Publication statusPublished - Dec 2001

Keywords

  • dopamine
  • bromocriptine
  • cognition
  • working memory
  • learning
  • Parkinson's disease
  • WORKING-MEMORY
  • PARKINSONS-DISEASE
  • PREFRONTAL CORTEX
  • COGNITIVE DEFICITS
  • BRAIN INJURY
  • LOBE LESIONS
  • PERFORMANCE
  • RECEPTOR
  • MECHANISMS
  • MODULATION

Cite this

Improved short-term spatial memory but impaired following the dopamine D-2 agonist bromocriptine reversal learning in human volunteers. / Mehta, M A ; Swainson, Rachel; Ogilvie, A D ; Sahakian, B J ; Robbins, T W .

In: Psychopharmacology, Vol. 159, No. 1, 12.2001, p. 10-20.

Research output: Contribution to journalArticle

@article{68747a1feb58434c96994fc099a54f3f,
title = "Improved short-term spatial memory but impaired following the dopamine D-2 agonist bromocriptine reversal learning in human volunteers",
abstract = "Rationale: Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function. Objectives: This study was designed to investigate the effects of 1.25 mg of the dopamine D-2 agonist bromocriptine on spatial working memory, planning and discrimination reversal learning in young healthy volunteers. Methods: Twenty volunteers were tested in a double-blind, placebo-controlled, crossover design. The cognitive assessment included tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) designed to test visuospatial recognition memory and spatial working memory. In addition, tests of spatial planning and discrimination reversal learning were used to assess the more general effects of bromocriptine. Tests of subjective feelings and motivation were also incorporated into the battery. Results: Bromocriptine enhanced the spatial memory span of subjects, whilst impairing their ability to reverse a learned probabilistic discrimination. Tests of recognition memory and planning were unaffected by the drug. The findings were not explained by chances in subjective mood or motivational measures. Conclusions: The pattern of findings observed here mirror medication-dependent observations seen in Parkinson's disease. The results, are discussed with reference to the different anatomical networks known to subserve performance of the differentially affected tasks.",
keywords = "dopamine, bromocriptine, cognition, working memory, learning, Parkinson's disease, WORKING-MEMORY, PARKINSONS-DISEASE, PREFRONTAL CORTEX, COGNITIVE DEFICITS, BRAIN INJURY, LOBE LESIONS, PERFORMANCE, RECEPTOR, MECHANISMS, MODULATION",
author = "Mehta, {M A} and Rachel Swainson and Ogilvie, {A D} and Sahakian, {B J} and Robbins, {T W}",
year = "2001",
month = "12",
doi = "10.1007/s002130100851",
language = "English",
volume = "159",
pages = "10--20",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Improved short-term spatial memory but impaired following the dopamine D-2 agonist bromocriptine reversal learning in human volunteers

AU - Mehta, M A

AU - Swainson, Rachel

AU - Ogilvie, A D

AU - Sahakian, B J

AU - Robbins, T W

PY - 2001/12

Y1 - 2001/12

N2 - Rationale: Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function. Objectives: This study was designed to investigate the effects of 1.25 mg of the dopamine D-2 agonist bromocriptine on spatial working memory, planning and discrimination reversal learning in young healthy volunteers. Methods: Twenty volunteers were tested in a double-blind, placebo-controlled, crossover design. The cognitive assessment included tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) designed to test visuospatial recognition memory and spatial working memory. In addition, tests of spatial planning and discrimination reversal learning were used to assess the more general effects of bromocriptine. Tests of subjective feelings and motivation were also incorporated into the battery. Results: Bromocriptine enhanced the spatial memory span of subjects, whilst impairing their ability to reverse a learned probabilistic discrimination. Tests of recognition memory and planning were unaffected by the drug. The findings were not explained by chances in subjective mood or motivational measures. Conclusions: The pattern of findings observed here mirror medication-dependent observations seen in Parkinson's disease. The results, are discussed with reference to the different anatomical networks known to subserve performance of the differentially affected tasks.

AB - Rationale: Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function. Objectives: This study was designed to investigate the effects of 1.25 mg of the dopamine D-2 agonist bromocriptine on spatial working memory, planning and discrimination reversal learning in young healthy volunteers. Methods: Twenty volunteers were tested in a double-blind, placebo-controlled, crossover design. The cognitive assessment included tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) designed to test visuospatial recognition memory and spatial working memory. In addition, tests of spatial planning and discrimination reversal learning were used to assess the more general effects of bromocriptine. Tests of subjective feelings and motivation were also incorporated into the battery. Results: Bromocriptine enhanced the spatial memory span of subjects, whilst impairing their ability to reverse a learned probabilistic discrimination. Tests of recognition memory and planning were unaffected by the drug. The findings were not explained by chances in subjective mood or motivational measures. Conclusions: The pattern of findings observed here mirror medication-dependent observations seen in Parkinson's disease. The results, are discussed with reference to the different anatomical networks known to subserve performance of the differentially affected tasks.

KW - dopamine

KW - bromocriptine

KW - cognition

KW - working memory

KW - learning

KW - Parkinson's disease

KW - WORKING-MEMORY

KW - PARKINSONS-DISEASE

KW - PREFRONTAL CORTEX

KW - COGNITIVE DEFICITS

KW - BRAIN INJURY

KW - LOBE LESIONS

KW - PERFORMANCE

KW - RECEPTOR

KW - MECHANISMS

KW - MODULATION

U2 - 10.1007/s002130100851

DO - 10.1007/s002130100851

M3 - Article

VL - 159

SP - 10

EP - 20

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -